Julayi 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
I-ACT Therapeutics kanye ne-GenScript ProBio basezinhlelweni zokusayina inkontileka yokuthuthukiswa nokukhiqizwa kwama-plasmid kanye nama-virus vectors wepayipi lokuqala le-ACT Therapeutics' Advanced CAR-T Platform (ACT platform), ezophinde inikezwe umsebenzi wokukhiqiza izinto zokusetshenziswa. kumaphayiphi alandelayo we-ACT Therapeutics. Inkontileka izohlanganisa ukukhiqizwa kwama-plasmids nama-virus vectors wepayipi lokuqala le-ACT Therapeutics' Advanced CAR-T Platform.
Ngenxa yalesi sivumelwano, i-GenScript ProBio iphakanyiselwe esimweni sokuba nguzakwethu womhlaba wonke okwazi ukusekela izinkundla ze-ACT ze-ACT therapeutics.
Inkundla ye-ACT iwubuchwepheshe besizukulwane esilandelayo sokwelashwa kweseli kanye nofuzo oluqondise kuma-antigen omdlavuza ngokufaka ufuzo olwenzelwe ukukhomba lawo ma-antigen kumaseli omzimba. Lezi zakhi zofuzo zilethwa kumaseli omzimba ngokusebenzisa ama-vectors amagciwane. I-GenScript ProBio inokuthuthukiswa kwenqubo ye-virus yekhwalithi ephezulu kanye nenkundla yesevisi yokuma eyodwa yokukhiqizwa kwe-GMP, kokubili okudingekayo ekuthuthukisweni kokwelashwa kwamaseli nofuzo.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing umdlavuza wegazi. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
UBrian H. Min, oyi-CEO ye-GenScript ProBio, uthe, “Sijabule kakhulu ukubambisana ne-ACT therapeutics ngokubambisana kwamasu, futhi sibheke ngabomvu ukusekela inkundla ye-ACT Therapeutics 'ACT njengozakwethu womhlaba wonke ngobuchwepheshe bethu esiqoqiwe.”
USogkyoung-Kong, oyi-CEO ye-ACT Therapeutics, uthe, “Sesiwaqedile amalungiselelo enkundla ye-ACT ukuthi iqhamuke emhlabeni wonke ngokusebenzisana kwamasu ne-GenScript ProBio. Sizosheshisa ukuthuthukiswa kwezindlela zokwelapha eziqondise umdlavuza oqinile ongalawuleki. ”
Mayelana ne-GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Ngasekupheleni kwenjongo “Yokusungula Ngokuhlanganyela”, i-GenScript ProBio izibophezele ekusizeni amakhasimende ukuthi afinyeze umugqa wesikhathi wokuthuthukiswa kwezidakamizwa zebhayoloji kusukela ekutholakaleni kuye ekudayiseni, ukwehlisa kakhulu izindleko ze-R&D nokwakha ikusasa elinempilo.
